Intravitreal Bevacizumab for diabetic retinopathy

J Fernando Arevalo, Rafael A. Garcia-Amaris

Research output: Contribution to journalArticle

Abstract

Diabetic retinopathy (DR) remains the major threat to sight in the working age population. Diabetic macular edema (DME) is a manifestation of DR that produces loss of central vision. Macular edema within 1 disk diameter of the fovea is present in 9% of the diabetic population. Proliferative diabetic retinopathy (PDR) is a major cause of visual loss in diabetic patients. In PDR, the growth of new vessels from the retina or optic nerve, is thought to occur as a result of vascular endothelial growth factor (VEGF) release into the vitreous cavity as a response to ischemia. Furthermore, VEGF increases vessel permeability leading to deposition of proteins in the interstitium that facilitate the process of angiogenesis and macular edema. This review demonstrates multiple benefits of intravitreal bevacizumab on DR including DME and PDR. The results indicate that intravitreal bevacizumab injections may have a beneficial effect on macular thickness and visual acuity (VA), independent of the type of macular edema that is present. Therefore, in the future this new treatment modality could replace or complement focal/ grid laser photocoagulation in DME. In addition, in PDR, this new option could be an adjuvant agent to PRP so that more selective therapy may be applied.

Original languageEnglish (US)
Pages (from-to)39-46
Number of pages8
JournalCurrent Diabetes Reviews
Volume5
Issue number1
DOIs
StatePublished - 2009

Fingerprint

Diabetic Retinopathy
Macular Edema
Vascular Endothelial Growth Factor A
Intravitreal Injections
Light Coagulation
Optic Nerve
Bevacizumab
Population
Visual Acuity
Retina
Permeability
Lasers
Ischemia
Therapeutics
Growth
Proteins

Keywords

  • Diabetic macular edema
  • Intravitreal bevacizumab
  • Panretinal photocoagulation
  • Proliferative diabetic retinopathy
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Intravitreal Bevacizumab for diabetic retinopathy. / Arevalo, J Fernando; Garcia-Amaris, Rafael A.

In: Current Diabetes Reviews, Vol. 5, No. 1, 2009, p. 39-46.

Research output: Contribution to journalArticle

Arevalo, J Fernando ; Garcia-Amaris, Rafael A. / Intravitreal Bevacizumab for diabetic retinopathy. In: Current Diabetes Reviews. 2009 ; Vol. 5, No. 1. pp. 39-46.
@article{d583a1f5f6014272b886427480bc2d8a,
title = "Intravitreal Bevacizumab for diabetic retinopathy",
abstract = "Diabetic retinopathy (DR) remains the major threat to sight in the working age population. Diabetic macular edema (DME) is a manifestation of DR that produces loss of central vision. Macular edema within 1 disk diameter of the fovea is present in 9{\%} of the diabetic population. Proliferative diabetic retinopathy (PDR) is a major cause of visual loss in diabetic patients. In PDR, the growth of new vessels from the retina or optic nerve, is thought to occur as a result of vascular endothelial growth factor (VEGF) release into the vitreous cavity as a response to ischemia. Furthermore, VEGF increases vessel permeability leading to deposition of proteins in the interstitium that facilitate the process of angiogenesis and macular edema. This review demonstrates multiple benefits of intravitreal bevacizumab on DR including DME and PDR. The results indicate that intravitreal bevacizumab injections may have a beneficial effect on macular thickness and visual acuity (VA), independent of the type of macular edema that is present. Therefore, in the future this new treatment modality could replace or complement focal/ grid laser photocoagulation in DME. In addition, in PDR, this new option could be an adjuvant agent to PRP so that more selective therapy may be applied.",
keywords = "Diabetic macular edema, Intravitreal bevacizumab, Panretinal photocoagulation, Proliferative diabetic retinopathy, Vascular endothelial growth factor",
author = "Arevalo, {J Fernando} and Garcia-Amaris, {Rafael A.}",
year = "2009",
doi = "10.2174/157339909787314121",
language = "English (US)",
volume = "5",
pages = "39--46",
journal = "Current Diabetes Reviews",
issn = "1573-3998",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Intravitreal Bevacizumab for diabetic retinopathy

AU - Arevalo, J Fernando

AU - Garcia-Amaris, Rafael A.

PY - 2009

Y1 - 2009

N2 - Diabetic retinopathy (DR) remains the major threat to sight in the working age population. Diabetic macular edema (DME) is a manifestation of DR that produces loss of central vision. Macular edema within 1 disk diameter of the fovea is present in 9% of the diabetic population. Proliferative diabetic retinopathy (PDR) is a major cause of visual loss in diabetic patients. In PDR, the growth of new vessels from the retina or optic nerve, is thought to occur as a result of vascular endothelial growth factor (VEGF) release into the vitreous cavity as a response to ischemia. Furthermore, VEGF increases vessel permeability leading to deposition of proteins in the interstitium that facilitate the process of angiogenesis and macular edema. This review demonstrates multiple benefits of intravitreal bevacizumab on DR including DME and PDR. The results indicate that intravitreal bevacizumab injections may have a beneficial effect on macular thickness and visual acuity (VA), independent of the type of macular edema that is present. Therefore, in the future this new treatment modality could replace or complement focal/ grid laser photocoagulation in DME. In addition, in PDR, this new option could be an adjuvant agent to PRP so that more selective therapy may be applied.

AB - Diabetic retinopathy (DR) remains the major threat to sight in the working age population. Diabetic macular edema (DME) is a manifestation of DR that produces loss of central vision. Macular edema within 1 disk diameter of the fovea is present in 9% of the diabetic population. Proliferative diabetic retinopathy (PDR) is a major cause of visual loss in diabetic patients. In PDR, the growth of new vessels from the retina or optic nerve, is thought to occur as a result of vascular endothelial growth factor (VEGF) release into the vitreous cavity as a response to ischemia. Furthermore, VEGF increases vessel permeability leading to deposition of proteins in the interstitium that facilitate the process of angiogenesis and macular edema. This review demonstrates multiple benefits of intravitreal bevacizumab on DR including DME and PDR. The results indicate that intravitreal bevacizumab injections may have a beneficial effect on macular thickness and visual acuity (VA), independent of the type of macular edema that is present. Therefore, in the future this new treatment modality could replace or complement focal/ grid laser photocoagulation in DME. In addition, in PDR, this new option could be an adjuvant agent to PRP so that more selective therapy may be applied.

KW - Diabetic macular edema

KW - Intravitreal bevacizumab

KW - Panretinal photocoagulation

KW - Proliferative diabetic retinopathy

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=65549136079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549136079&partnerID=8YFLogxK

U2 - 10.2174/157339909787314121

DO - 10.2174/157339909787314121

M3 - Article

C2 - 19199897

AN - SCOPUS:65549136079

VL - 5

SP - 39

EP - 46

JO - Current Diabetes Reviews

JF - Current Diabetes Reviews

SN - 1573-3998

IS - 1

ER -